Amring Pharmaceuticals Inc has voluntarily recalled 48,989 bottles of Lysteda (tranexamic acid) USP Tablets, 650 mg. The recall was issued because laboratory tests showed the medication failed to meet quality specifications for impurities and conductivity. No injuries or incidents have been reported in connection with this issue, and the product was distributed nationwide to pharmacies and healthcare providers.
The tablets may contain impurities or degradation products that do not meet standard quality requirements. While the risk to patients is considered low, these issues can compromise the long-term quality and safety of the medication.
You have 2 options:
Recall Number: D-0871-2023
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.